Brazil to get at least 300,000 packs of Russian antiviral drug Avifavir by end of 2021
Russian pharmaceutical company Chromis will deliver at least 300,000 packs of Avifavir, a Russian antiviral drug for COVID-19 therapy, the Russian Direct Investment Fund (RDIF) said in a statement on Tuesday.
"Chromis, a company of the Russian Direct Investment Fund (RDIF) and the ChemRar Group, announces the signing of an agreement on licensing and cooperation with Brazil’s Axis BioTec in delivering Avifavir, the first Russian medicine for the treatment of COVID-19, to Brazil," the statement said.
Chromis is to deliver at least 100,000 packs of the medicine to Brazil by the end of 2020. Next year, Brazil is expected to purchase at least 200,000 packs.
"Latin America and Brazil in particular are now going through difficult times due to the novel coronavirus, and our medicine will allow efficient therapy of patients and reduce the pressure on medical facilities. We are ready to satisfy the growing foreign demand for Avifaviar and are open for new international partnerships," Head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev said.
Earlier on Tuesday, Dmitriev wrote in his column for the Newsweek magazine that more than 50 countries, including Belarus, Kazakhstan, Colombia, Brazil, Bulgaria, Mexico, Saudi Arabia and Peru, had submitted requests to procure Avifavir.